Imagenetix Inc (IAGX)

[houtheman]

IAGX coverage starts $1.25 price target

http://finance.yahoo.com/news/RedChip-Visibility-Initiates-pz-4180667132.html?x=0&.v=1

ORLANDO, Fla., Sept. 30, 2009 (GLOBE NEWSWIRE) -- RedChip Visibility, a division of RedChip Companies, Inc., has initiated coverage on Imagenetix Inc. (OTCBB:IAGX - News), an innovator of scientifically tested, natural-based, proprietary, bioceutical products developed to enhance human health on a global basis.
Related Quotes
Symbol Price Change
IAGX.OB 0.81 0.00
Chart for IMAGENETIX INC
{"s" : "iagx.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""}

Harry Russell, MBA, RedChip Research Analyst, reported:

"Imagenetix is a neutraceutical company with a suite of proprietary, scientifically tested, validated, and naturally based products. The Company's main focus is on anti-inflammation; and, its lead product, Celadrin(R), is being strategically positioned with mass marketers. With the existing traction that the Company has with Celadrin, there should be substantial operating leverage going forward and a more seamless positioning of the Company's other products.

The Company is well-positioned in very large markets; and, although these markets are competitive, most of the challenges that are presented to new entrants are behind them. Finally, because of their large distribution capabilities, revenue growth can be generated in a very short period of time.

Because the Company has its most challenging days behind it and, further, because of the validation they have earned with large vendor organizations, we feel now is a critical time for investment. For this reason, we are initiating coverage of IAGX with a 'Speculative Buy' recommendation and a 12-month price target of $1.25."